Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Mar 5;11:12. doi: 10.1186/s13041-018-0355-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 4 — ZBD-2-induced reversal of glutamate receptor expression in PPD mice. a, d The representative Western blot analysises for GluA1, p-GluA1-Ser845, GluN2A, and GluN2B are presented in the BLA. b, c, f ZBD-2 administration reversed the increased levels of GluA1 (b), p-GluA1-Ser845 (c), and GluN2B (f) expression in the PPD model mice. The effects of ZBD-2 were blocked by PK11195. e ZBD-2 did not affect the levels of GluN2A-containing NMDA receptors in the BLA of PPD mice. There were no differences between ZBD-2 and fluoxetine treatment groups. n = 5 in each group. *p < 0.05 compared with the control; ^#p < 0.05 compared with the PPD model; ^$p < 0.05 compared with the ZBD-2 group. PK: PK11195